{"doi":"10.1038/s41591-024-02875-1","title":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","abstract":"Abstract Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10 6 CAR-T cells per infusion cycle was achieved for arm 5; however, other arms either did not test or achieve this dose due to manufacturing feasibility. A recommended phase 2 dose will be refined in future studies based on data from this trial. Stable disease or better was achieved in 50% (29/58) of patients, with two partial responses, one complete response and a second complete response after additional CAR-T cycles off protocol. For rGBM, median overall survival for all patients was 7.7 months and for arm 5 was 10.2 months. Central nervous system increases in inflammatory cytokines, including IFNγ, CXCL9 and CXCL10, were associated with CAR-T cell administration and bioactivity. Pretreatment intratumoral CD3 T cell levels were positively associated with survival. These findings demonstrate that locoregional IL-13Rα2-targeted CAR-T therapy is safe with promising clinical activity in a subset of patients. ClinicalTrials.gov Identifier: NCT02208362 .","journal":"Nature Medicine","year":2024,"id":416119,"datarank":3.8279339040652713,"base_score":5.733341276897746,"endowment":5.733341276897746,"self_citation_contribution":0.860001191534662,"citation_network_contribution":2.9679327125306094,"self_endowment_contribution":0.860001191534662,"citer_contribution":2.9679327125306094,"corpus_percentile":null,"corpus_rank":null,"citation_count":308,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9608,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02208362"],"GEO":["GSE255850"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":810881,"name":"Jonathan Hibbard","orcid":null,"position":1,"is_corresponding":false},{"id":249973,"name":"Darya Alizadeh","orcid":"0000-0003-1676-1181","position":2,"is_corresponding":false},{"id":460080,"name":"M. Suzette Blanchard","orcid":null,"position":3,"is_corresponding":false},{"id":794241,"name":"Heini M. Natri","orcid":"0000-0003-4698-6103","position":4,"is_corresponding":false},{"id":249971,"name":"Dongrui Wang","orcid":"0000-0002-0859-7281","position":5,"is_corresponding":false},{"id":569666,"name":"Julie R. Ostberg","orcid":"0000-0001-5439-3725","position":6,"is_corresponding":false},{"id":249972,"name":"Brenda Aguilar","orcid":"0000-0002-6408-8422","position":7,"is_corresponding":false},{"id":808098,"name":"Jamie R. Wagner","orcid":"0000-0001-7961-3253","position":8,"is_corresponding":false},{"id":861474,"name":"Jinny Paul","orcid":"0000-0002-6863-6406","position":9,"is_corresponding":false},{"id":249976,"name":"Renate Starr","orcid":"0000-0002-2200-6900","position":10,"is_corresponding":false},{"id":810880,"name":"Robyn A. Wong","orcid":null,"position":11,"is_corresponding":false},{"id":846010,"name":"Wuyang Chen","orcid":"0000-0002-7746-4191","position":12,"is_corresponding":false},{"id":1161865,"name":"Noah Shulkin","orcid":null,"position":13,"is_corresponding":false},{"id":717974,"name":"Maryam Aftabizadeh","orcid":"0009-0001-3890-3315","position":14,"is_corresponding":false},{"id":1199015,"name":"Aleksandr Filippov","orcid":"0000-0001-8084-661X","position":15,"is_corresponding":false},{"id":434645,"name":"Ammar Chaudhry","orcid":"0000-0002-2126-0587","position":16,"is_corresponding":false},{"id":95491,"name":"Julie A. Ressler","orcid":"0000-0003-3086-3045","position":17,"is_corresponding":false},{"id":460083,"name":"Julie Kilpatrick","orcid":null,"position":18,"is_corresponding":false},{"id":1176654,"name":"Paige Myers-McNamara","orcid":null,"position":19,"is_corresponding":false},{"id":514805,"name":"Mike Y. Chen","orcid":"0000-0001-5410-652X","position":20,"is_corresponding":false},{"id":238409,"name":"Leo D. Wang","orcid":"0000-0002-2945-9005","position":21,"is_corresponding":false},{"id":274023,"name":"Russell C. Rockne","orcid":"0000-0002-1557-159X","position":22,"is_corresponding":false},{"id":362105,"name":"Joseph Georges","orcid":"0000-0002-7630-8007","position":23,"is_corresponding":false},{"id":225593,"name":"Jana Portnow","orcid":"0000-0002-4257-0891","position":24,"is_corresponding":false},{"id":274020,"name":"Michael E. Barish","orcid":"0000-0003-3011-4861","position":25,"is_corresponding":false},{"id":775854,"name":"Massimo D’Apuzzo","orcid":"0000-0001-8146-0997","position":26,"is_corresponding":false},{"id":12172,"name":"Nicholas E. Banovich","orcid":"0000-0003-2604-3247","position":27,"is_corresponding":false},{"id":249979,"name":"Stephen J. Forman","orcid":"0000-0002-2803-4152","position":28,"is_corresponding":false},{"id":249978,"name":"Behnam Badie","orcid":"0000-0001-9811-9306","position":29,"is_corresponding":false},{"id":249980,"name":"Christine E. Brown","orcid":"0000-0003-4915-8207","position":0,"is_corresponding":true}],"reference_count":78,"raw_metadata":null,"created_at":"2026-07-19T01:56:20.964471Z","pmid":"38454126","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}